Microbiome Therapeutics US

Memo

Microbiome Therapeutics US brings together leading experts from across the human microbiome therapeutics field to explore the latest progress in finding the most effective route from microbiome drug discovery through to commercial success. The meeting provides the ultimate platform to get involved in the latest discussions with like-minded professionals surrounding the latest clinical trials, manufacturing and scale-up challenges, funding solutions and commercialization strategies to take these products to market. Join the likes of Flagship Pioneering, Siolta Therapeutics, Finch Therapeutics and many more to benchmark your end-to-end microbiome drug strategy with practical industry insights, case studies, shared experiences and lessons learned to help you stay ahead of the curve. Plus, ensure you're up to date with the latest regulatory guidance with direct feedback from the FDA and seek out funding opportunities to take your pipeline to the next level. Prices:Industry - For Pharma, Biotech, Microbiome Therapeutics and Supplier, Vendor, Consultant, Technology Provider Companies: USD 1699.0Academic: USD 850.0 Speakers: Julia Barrett, Senior Clinical Consultant at Biologics Consulting, Keith Batchelder, MD, CEO and Founder at Genomic Healthcare Strategies, JP Benya, VP, Commercial at Assembly Biosciences, David Berry, Partner at Flagship Pioneering, Rodolphe Clerval, CBO at Enterome, David Donabedian, PhD, CEO, Co-Founder at Axial Biotherapeutics, Akintunde Emiola, PhD, PostDoctoral associate at The Jackson Laboratory, Michalis Hadjithomas, Microbiome Lead Scientist at DNANexus, Zain Kassam, MD, co-founder and Executive VP at Finch Therapeutics, Nikole Kimes, PhD, Founder and Chief Scientific Officer at Siolta Therapeutics, David Kyle, CEO at Evolve BioSystems Inc, Robert Langer, SCD, David H. Koch Institute Professor at Massachusetts Institute of Technology, Mark Smith, CEO at Finch Therapeutics, Erik Spek, PhD, Vice President, Head of Intellectual Property at Vedanta Biosciences, Inc., Lily Ting, PhD, Head of RandD at Commense, Kamal Velmurugan, Microbiologist, Primary Reviewer at FDA, James Weston, MBA, Senior Vice President of Regulatory Affairs at Seres Therapeutics Time: 8:00 am - 6:30 pm Venue details: Hynes Convention Center,900 Boylston Street,Boston,02115,USA